Impact of Smoking, Physical Training and Weight Reduction on FVII, PAM and Hemostatic Markers in Sedentary Men

Summary

The variations of FVII, PAI-1, TAT complexes, fibrinopeptide A, D-Dimers and beta thromboglobulin plasma levels were studied on 30 sedentary men, smokers and non-smokers, who were admitted to a 6 months’ program of physical training and smoking cessation. After 3 months of intervention, sustained physical training was associated with the decrease of FVII and PAI-1 levels. Mild exercise performed during a second 3-month period could maintain normal FVII and PAI-1 activities but participants who stopped the training increased their FVII and PAI-1 plasma levels. FVII was not influenced by smoking habits. Smoking cessation seemed to slightly potentiate the decrease of PAI-1 levels associated with mild exercise. Overweight, FVII and PAI-1 levels were correlated and the weight reduction induced by training was related to the changes in the factors. In smokers, physical exercise was associated with a significant increase of hemostatic markers. This exercise-induced variation disappeared after 3 months of intervention in participants who stopped smoking and reappeared in those who smoked again after 6 months of intervention. This finding was not influenced by the physical training program.

• References

• 1 Hopkins PN, Williams RR. A survey of suggested coronary risk factors. Atherosclerosis 1981; 40: 1-52
• 2 Castelli WP. Epidemiology of coronary heart disease. The Framingham Study. Am J Med 1984; 76: 4-12
• 3 Wildhelmsen L, Svarsudd K, Korsan-Bengtsen K, Larsson B, Velin L, Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 1984; 311: 501-505
• 4 Kannel WB, D’Agostino RB, Belanger AJ. Fibrinogen, cigarette smoking, and risk of cardiovascular disease: insights from the Framingham study. Am Heart J 1987; 113: 1006-1010
• 5 Balleisen L, Schulte H, Assmann G, Epping PH, Van de Loo J. Coagulation factors and the progress of coronary heart disease. Lancet 1987; ii: 461
• 6 Meade TW, North WR S, Chakrabarti R, Stirling Y, Haines AP, Thompson SG, Brozovic M. Haemostatic function and cardiovascular death: early results of a prospective study. Lancet 1980; i: 1050-1053
• 7 Meade TW. Factor VII and ischaemic heart disease: epidemiological evidence. Haemostasis 1983; 13: 178-185
• 8 Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR, North WR, Haines AP, Stirling Y, Imeson JD, Thompson BA. Haemostatic function and ischaemic heart disease: principal results of the Northwick Peak Heart Study. Lancet 1986; ii: 533-537
• 9 Paramo JA, Colucci M, Collen D, Van de Werf F. Plasminogen activator inhibitor in the blood of patients with coronary artery disease. Br Med J 1985; 291: 573-574
• 10 Hamsten A, Wiman B, De Faire U, Blombäck M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985; 313: 1557-1563
• 11 Hamsten A, De Faire U, Walldins G, Dahlen G, Szamosi A, Landon C, Blombäck M, Wiman B. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987; ii: 3-9
• 12 Collen D, Juhan-Vague I. Fibrinolysis and atherosclerosis. Semin Thromb Haemostas 1988; 14: 180-183
• 13 Thomas M. Idées actuelles sur le traitement de l’obésité. Rev Med Int 1986; 7: 329-333
• 14 Constant G, Gouault-Heilmann M, Martinolli JL. Heparin inactivation during blood storage. Its prevention by blood collection in citric acid, theophylline, adenosine, dipyridamole - CTAD mixture. Thromb Res 1983 31. 365-374
• 15 Caen J, Larrieu MJ, Samama M. L’hémostase. Methodes d’exploration et diagnostique pratique. L’expansion Scientifique Fran�aise, Paris 1980; 189
• 16 Eriksson E, Rånby M, Gyzander E, Risberg B. Determination of plasminogen activator inhibitor in plasma using t-PA and a chromogenic single-point poly-D-lysine stimulated assay. Thromb Res 1988; 50: 91-101
• 17 Masson C, Anglès-Cano E. Kinetic analysis of the interaction between plasminogen activator inhibitor-1 and tissue-type plasminogen activator. Biochem J 1988; 256: 237-244
• 18 Juhan-Vague I, Vague P, Alessi MC, Badier C, Valadier J, Aillaud MF, Atlan C. Relationship between plasma insulin, triglyceride, body mass index, and plasminogen activator inhibitor 1. Diab Metab 1987; 13: 331-6
• 19 Vague P, Juhan-Vague I, Aillaud MF, Badier C, Viard R, Alessi MC, Collen D. Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level and relative body weight in normal and obese subjects. Metabolism 1986; 2: 250-253
• 20 Tremblay A, Nadeau A, Després JP, Thériault G, Bouchard C. Effets d’une perte de poids induite par l’entrainement à l’exercise sur les niveaux d’insuline plasmatique: contribution de la sécrétion et de la clearance d’insuline. Med Sci 1988 09A
• 21 Vague P, Juhan-Vague I, Alessi MC, Badier C, Valadier J. Metformin decreases the high plasminogen activator inhibition capacity, plasma insulin and triglyceride levels in non-diabetic obese subjects. Thromb Haemostas 1987; 57: 326-328
• 22 Carvalho de Souza J, Bruckert E, Soria C, Caen JP. Phospholipase C sensitive FVII activity and FVII antigen in hypertriglyceridemia. Nouv Rev Fr Hematol 1989; 31: 13-15
• 23 Carvalho de Souza J, Soria C, Ayrault-Jarrier M, Pastier D, Bruckert E, Amiral J, Bereziat G, Caen JP. Association between coagulation factors VII and X with triglyceride rich lipoproteins. J Clin Pathol 1988; 41: 940-944
• 24 Morris JN, Everitt MG, Pollard R, Chave SP W, Semmence AM. Vigourous exercise in leisure time: protection against coronary heart disease. Lancet 1980; ii: 1207-1210
• 25 Hermanson B, Omenn GS, Kronmal RA, Gersh BJ. Beneficial six-year outcome of smoking cessation in older men and women with coronary artery disease. Results from the CASS Registry. N Engl J Med 1988; 319: 1365-1369